Medix Biochemica increases its capability in diagnostic base Matrices through the acquisition of Bioresource Technology

Medix Biochemica increases its capability in diagnostic base Matrices through the acquisition of Bio ...

Medix Biochemica has acquired 100% of its shares in Bioresource Technology (BRT) to broaden its base matrix capabilities and strengthen its local presence in the United States market. Following the acquisition, Medix Biochemica''s business unit will provide its customers with a comprehensive supply of raw materials for their IVD quality control products. BRTs operations will remain in Weston, Florida, and CEO Ron Dilling will remain as strategic advisors.

BRT, founded in 1984 by Dr. David Reichenbach, is a provider of high-quality base matrices and other critical raw materials to many IVD manufacturers across the world. With a high focus on immunoassay, clinical chemistry, and molecular diagnostic assay and QC materials, the company manufactures its products in a state of the art, ISO 13485:2016 certified, a 26,000 square foot facility in Weston, Florida, and employs a highly skilled workforce.

"We have the potential to broaden our offering to IVD firms across the globe. "There is an excellent complementary offering between our portfolios, allowing Medix Biochemica to be a comprehensive partner for IVD companies who require quality raw materials for QC products. "Our objective is to be the first-choice partner for the IVD industry, and the team at BRT takes us one step closer."

"We are excited about joining Medix Biochemica," said Derik Reichenbach, head of BRT. "Building long-term relationships with our customers have always been essential to our success," says Reichenbach. "We are now able to reach even more IVD customers across the globe. We are very interested in contributing to Medix Biochemica''s strong growth."

You may also like: